Inogen (FRA:6IO) Moat Score: 4/10 (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6IO Inogen Inc FRA:6IO
66 GF Score
Price €5.95
GF Value €6.31
! 3 Warning Signs
View Full Analysis

What is Inogen Moat Score?

Inogen FRA:6IO +2.59% 66 Moat Score is 4 as of Aug. 06, 2026. GuruFocus rates FRA:6IO with a GF Score™ of 66/100 and a GF Value™ of €6.31. The stock has 3 warning signs investors should review. Among 837 Medical Devices & Instruments companies, Inogen ranks better than 83.15% on this metric.

Inogen has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Inogen has Narrow Moat: Inogen Inc has a discernible moat due to its innovative portable oxygen concentrators and some intellectual property. However, the medical device market is competitive, and while it has some pricing power, it lacks significant network effects and customer switching costs.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Inogen might have Narrow Moat - Discernible but modest moat.

Inogen  (FRA:6IO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Inogen Moat Score Related Terms

FRA:6IO vs QSI, APYX, QTRX: Moat Score Comparison

For the Medical Devices subindustry, Inogen's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inogen Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inogen's Moat Score distribution charts can be found below:

* The bar in red indicates where Inogen's Moat Score falls into.


FRA:6IO
66GF Score
Inogen Inc FRA:6IO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Inogen (FRA:6IO) has a Moat Score of 4 as of Aug. 06, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Inogen ranks #141 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 16.8%.
Is Inogen's Moat Score too high?
Inogen's current Moat Score is 4. Based on the distribution chart, Inogen ranks #141 out of 837 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Inogen has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Inogen's Moat Score compare to QSI and APYX?
According to the Medical Devices & Instruments industry distribution chart, Inogen ranks #141 out of 837 companies for Moat Score. This places Inogen in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Inogen's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inogen stock overvalued right now?
Inogen (FRA:6IO) has a current Moat Score of 4. The stock's GF Value™ is €6.31, compared to a current price of €5.95 — trading 5.7% below its estimated fair value. The current Moat Score is 4. Inogen's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Inogen (FRA:6IO), the current Moat Score is 4 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inogen (FRA:6IO) Overvalued in 2026?

Based on GuruFocus' analysis, Inogen stock appears to be undervalued. The current stock price of €5.95 is trading 5.7% below its estimated GF Value™ of €6.31.

Key valuation signals for FRA:6IO:

  • Moat Score: 4
  • GF Value™: €6.31 vs. price of €5.95 (5.7% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the FRA:6IO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inogen Business Description

Other Exchanges INGN:USA6IO:Germany
Address 500 Cummings Center, Suite 2800, Beverly, MA, USA, 01915
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
66GF Score

Get the complete analysis for FRA:6IO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.95
Price
€6.31
GF Value